https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42269 Wed 20 Sep 2023 12:13:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49081 Wed 03 May 2023 16:22:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45616 Wed 02 Nov 2022 14:34:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47048 30 days: 39% vs. 7%; p < 0.001) and sigmoid sinus thrombosis (86% vs. 51%; p < 0.001), and less frequently had parenchymal lesions (31% vs. 55%; p = 0.013) at baseline imaging. Clinical outcome at last follow-up did not differ between patients with and without dAVF. Additionally, five patients were confirmed with dAVF from non-consecutive CVT cohorts. Among all patients with CVT and dAVF, 17/34 (50%) had multiple fistulas and 23/34 (68%) had cortical venous drainage. Of 34 patients with dAVF with 36 separate CVT events, 3/36 fistulas (8%) were diagnosed prior to, 20/36 (56%) simultaneously and 13/36 after (36%, median 115 [IQR 38–337] days) diagnosis of CVT. Conclusions: Dural arteriovenous fistulas occur in at least 2% of CVT patients and are associated with chronic CVT onset, older age and male sex. Most CVT-related dAVFs are detected simultaneously or subsequently to diagnosis of CVT.]]> Tue 13 Dec 2022 14:44:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18930 Sat 24 Mar 2018 07:59:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17946 Sat 24 Mar 2018 07:56:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27967 Sat 24 Mar 2018 07:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30017 Sat 24 Mar 2018 07:28:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4717 Sat 24 Mar 2018 07:21:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22849 P < 0.001) and 34% (±10%, P < 0.001), respectively. Conclusions: Our data suggest that the genetic contribution to the risk of stroke may be higher in young-onset ischaemic stroke, although the difference was not statistically significant.]]> Sat 24 Mar 2018 07:16:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>